LLY
$LLY
Eli Lilly and Company
Pharmaceutical heavyweight known for weight-loss drugs Mounjaro and Zepbound.
HealthcareSubscribers
15
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
LLY: Growth from Blockbusters, Valuation in Focus
Eli Lilly ($LLY) is riding strong momentum from its GLP-1 and oncology franchises, producing double-digit returns and analyst optimism heading into late-2026. Valuation is rich, so catalysts and execution will determine near-term upside.
Aug 1, 2026